Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced its 2025 priorities and upcoming catalysts for ...

BRAF V600E 突变在结直肠癌（CRC）中是一个重要的生物标志物，约占所有结直肠癌病例的 10%。这一突变通常与肿瘤的侵袭性、预后不良以及对常规化疗的耐药性相关联[1]。研究显示，BRAF V600E 突变导致肿瘤细胞激活 MAPK ...

Below is a review of novel drug and biological products approved by the Food and Drug Administration (FDA) in 2024. The list includes several groundbreaking therapies that are expected to change the ...

R-5780, an oral immuno-oncology drug designed to activate gut-regulated immune pathways, will now be evaluated in a phase 1 ...

pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of PAS-004 in patients with MAPK pathway-driven advanced solid tumors with a documented RAS, NF1 or RAF mutation or patients who ...

Cerebral vascular malformations (CVMs), including cerebral arteriovenous malformations (AVMs) and cavernous malformations (CCMs), have long posed challenges due to their complex origins and severe ...

1 Department of Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China 2 Department of Obstetrics and Gynecology, Taizhou Hospital of Zhejiang Province ...

A groundbreaking review highlights significant advancements in the understanding and treatment of cerebral vascular ...

FORE Biotherapeutics highlights pipeline achievements for its oncology programme; Provides objectives for 2025: Philadelphia Saturday, January 11, 2025, 17:00 Hrs [IST] FORE Bioth ...

[40] This emphasizes the importance of knowing not only a patient's BRAF mutant status, but also RAS mutant status and highlights the potential for several growth pathways to influence one another ...